Natixis Advisors LLC Decreases Holdings in Moderna, Inc. (NASDAQ:MRNA)

Natixis Advisors LLC decreased its holdings in Moderna, Inc. (NASDAQ:MRNA) by 83.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,574 shares of the company’s stock after selling 58,936 shares during the period. Natixis Advisors LLC’s holdings in Moderna were worth $773,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Commerzbank Aktiengesellschaft FI lifted its holdings in shares of Moderna by 1.7% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock worth $660,000 after acquiring an additional 93 shares during the last quarter. CVA Family Office LLC lifted its holdings in shares of Moderna by 21.6% in the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company’s stock worth $64,000 after acquiring an additional 96 shares during the last quarter. Claro Advisors LLC lifted its holdings in shares of Moderna by 2.0% in the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock worth $659,000 after acquiring an additional 108 shares during the last quarter. McAdam LLC lifted its holdings in shares of Moderna by 1.1% in the 2nd quarter. McAdam LLC now owns 11,075 shares of the company’s stock worth $1,315,000 after acquiring an additional 117 shares during the last quarter. Finally, 180 Wealth Advisors LLC lifted its holdings in shares of Moderna by 1.1% in the 2nd quarter. 180 Wealth Advisors LLC now owns 14,868 shares of the company’s stock worth $1,826,000 after acquiring an additional 160 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on MRNA. Berenberg Bank began coverage on shares of Moderna in a report on Tuesday, November 19th. They issued a “hold” rating and a $42.00 price objective for the company. Wolfe Research started coverage on shares of Moderna in a research note on Friday, November 15th. They issued an “underperform” rating and a $40.00 target price on the stock. Leerink Partners decreased their target price on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research note on Tuesday, September 17th. UBS Group decreased their target price on shares of Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Finally, TD Cowen decreased their target price on shares of Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research note on Friday, September 13th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $83.26.

Insider Buying and Selling

In related news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. The trade was a 7.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 1,147 shares of company stock worth $76,245 in the last quarter. Corporate insiders own 15.70% of the company’s stock.

Moderna Stock Performance

Shares of MRNA stock opened at $43.39 on Thursday. The stock has a market cap of $16.70 billion, a PE ratio of -7.46 and a beta of 1.69. The company’s fifty day moving average price is $53.32 and its 200-day moving average price is $92.28. Moderna, Inc. has a 12 month low of $35.80 and a 12 month high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The company had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. Moderna’s revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.39) EPS. On average, equities analysts expect that Moderna, Inc. will post -9.44 EPS for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.